Cellectis (CLLS)

• Market cap: $363M
• 1 day: -8.35%
• 5 days: -11.71%
• 1 month: -1.36%
• 3 months: 97.81%
• 6 months: 162.32%
• Year to date: 100%
• 1 year: 96.74%
• 5 years: -78.81%
• 10 years: -86.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222